Navigation Links
Pharmion Corporation Announces 2007 Operating Results
Date:2/19/2008

rm Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Pharmion's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include the outcome of ongoing clinical trials, the status and timing or regulatory approvals for Pharmion's product candidates; the impact of competition from other products under development by Pharmion's competitors; the regulatory environment and changes in the health policies and structure of various countries; uncertainties regarding market acceptance of products newly launched, currently being sold or in development; Pharmion's ability to successfully acquire rights to, develop and commercialize additional pharmaceutical products; failure of third-party manufacturers to produce the product volumes required on a timely basis, fluctuations in currency exchange rates, and other factors that are discussed in Pharmion's filings with the U.S. Securities and Exchange Commission, including those discussed in the "Risk Factors" section of Pharmion's Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Forward-looking statements speak only as of the date on which they are made, and Pharmion undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

PHARMION CORPORATION

CONSOLIDATED FINANCIAL RESULTS

(In thousands, except for per share amounts)

Unaudited

Three Months Ended Twelve Months Ended<
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmion Corporation to Announce Third Quarter 2007 Financial Results
2. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
3. Pharmion Corporation to Present at Bear Stearns 2007 Healthcare Conference
4. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
5. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
6. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
7. VLST Corporation Announces Board and Executive Management Appointments
8. AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II
9. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
10. LifeCell Corporation Revises Full Year 2007 Preliminary Results and Schedules Fourth Quarter 2007 Financial Results Conference Call; February 27, 2008 at 10:00 a.m. Eastern
11. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 SPIE Fellow Glenn Boreman, ... Optical Science and Director of the Center for Optoelectronics ... at Charlotte, and co-founder and Chairman of the Board ... the 2015 Vice President of SPIE, the international society ... Stahl announced recent election results at the Annual General ...
(Date:8/28/2014)... 28, 2014 “This kit has an improved ... from 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin ... benefit to plant owners and USDA-GIPSA inspection agencies that have ... Testing can take place in a matter of minutes with ... plant test the feed and grain before accepting it, but ...
(Date:8/28/2014)... , Aug. 28, 2014 ... a new market research report ... Whole Exome Sequencing ... (Library Preparation, Target Enrichment), by ... by Synthesis), by Application (Cancer, ...
(Date:8/28/2014)... SunTrust Robinson Humphrey (STRH) today announced the ... research team in biotechnology and oilfield services.  ... demonstrates our commitment to providing our valued institutional ... decision making," said Biff Woodruff , Head ... significant investments in differentiated content at a time ...
Breaking Biology Technology:Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... SAN FRANCISCO, September 22, 2010 ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... Sept. 22 RF Technologies®, a leading provider of ... announces the hiring of Mark Harwood as company President. ... Inc. and former President and CEO of Arjo, Inc. ... of success in the high-tech, healthcare and medical device ...
... Advanced Cell Technology, Inc. ("ACT"; OTC Bulletin Board: ... Scientific Officer, Robert Lanza, MD, and Kwang-Soo Kim, PhD, ... National Institutes of Health (NIH) Director,s Opportunity Award for ... Better Treatments" under the American Recovery & Reinvestment Act ...
Cached Biology Technology:Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 2Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 3Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 4Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 5Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 6Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 7Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 8Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 9Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 10RF Technologies® Names Mark Harwood New President 2Drs. Robert Lanza and Kwang-Soo Kim Win Prestigious NIH Director's Award 2Drs. Robert Lanza and Kwang-Soo Kim Win Prestigious NIH Director's Award 3
(Date:8/29/2014)... (Aug. 29, 2014) Scientists at the Barshop Institute ... of Medicine at the UT Health Science Center at ... the tissues of the longest-lived rodent, the naked mole ... the cells of naked mole rats protects and alters ... damaged and obsolete proteins. , The factor also protects ...
(Date:8/29/2014)... A leading U.S. Ebola researcher from the University of Texas ... a blend of three monoclonal antibodies can completely protect monkeys ... days after infection, at a time when the disease is ... written an editorial for Nature discussing advances in ... Marburg virus are among the most deadly of pathogens, with ...
(Date:8/29/2014)... Dartmouth researchers explored the type and number of connections ... assortativity plays on robustness in a study published in ... study found that the assortativity signature contributes to a ... seems that varying the out-out assortativity of TFN models ... of the other three types of assortativity," said Dov ...
Breaking Biology News(10 mins):Factor in naked mole rat's cells enhances protein integrity 2Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Assortativity signatures of transcription factor networks contribute to robustness 2
... represent a major and unsolved health issue worldwide. The ... disease, highlighting the urgent need for better knowledge of ... of researchers led by scientists at the Salk Institute ... study kidney diseases, opening new avenues for the future ...
... University of Illinois anthropology professor Ripan Malhi ... first came to the Americas and what happened to them once ... at the meeting, " Ancient DNA: The First Three Decades ," ... Malhi, an affiliate of the Institute for Genomic Biology ...
... cells offer the opportunity to harvest abundant, renewable energy. Although ... spectrum, most solar energy is in the infrared. There is ... are efficient in the infrared but waste much of the ... part of the spectrum. When a photon is absorbed ...
Cached Biology News:Salk scientists for the first time generate 'mini-kidney' structures from human stem cells 2Salk scientists for the first time generate 'mini-kidney' structures from human stem cells 3Ancient, modern DNA tell story of first humans in the Americas 22 for 1 in solar power 2
... Ideal for staining westerns and includes stickers ... Pour spouts in each corner facilitate pouring ... be used for identification. Lid is designed ... for staining several gels simultaneously. Lid also ...
ID clarifier: non-treated with lid...
... Staccato Series of systems provide fast and reliable scalable ... drug development laboratories. Staccato systems are available in three ... Systems Series. ... All Staccato ...
... Staccato Custom Series Systems provide ... drug discovery, genomics, proteomics and drug ... built specifically to customer specifications, providing ... individual needs. Staccato Custom Systems ...
Biology Products: